Veligrotug

Veligrotug
Clinical data
Trade namesLumvoa
Other namesAVE-1642, VRDN-001, veligrotug-vvze
AHFS/Drugs.comMultum Consumer Information
License data
Routes of
administration		Intravenous
Drug classInsulin-like growth factor-1 receptor inhibitor
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
FormulaC6580H10160N1752O2038S40
Molar mass147702.29 g·mol−1

Veligrotug, sold under the brand name Lumvoa, is a monoclonal antibody medication used for the treatment of thyroid eye disease. It is an insulin-like growth factor-1 receptor inhibitor. It is given via intravenous injection.

Veligrotug was approved for medical use in the United States in June 2026.

Medical uses

Veligrotug is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.

Society and culture

Veligrotug was approved for medical use in the United States in June 2026.

Names

Veligrotug is the international nonproprietary name.

Veligrotug is sold under the brand name Lumvoa.

References

  1. 1 2 3 4 5 "Lumvoa- veligrotug injection". DailyMed. 29 June 2026. Retrieved 3 August 2026.
  2. ↑ Kaplan R, Zhao Y, Tsai J, Dickinson B, Swanson T, Foster K, et al. (December 2025). "Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease". mAbs. 17 (1) 2585616. doi:10.1080/19420862.2025.2585616. PMC 12629334. PMID 41250603.
  3. ↑ "Lumvoa (veligrotug-vvze) FDA Approval History". Drugs.com. 28 June 2026. Retrieved 1 July 2026.
  4. ↑ "Drugs@FDA: FDA-Approved Drugs". Food and Drug Administration (FDA). Retrieved 1 July 2026.
  5. ↑ World Health Organization (2023). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 90". WHO Drug Information. 37 (3). hdl:10665/373341.
  6. ↑ "Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease". Viridian Therapeutics. 26 June 2026. Retrieved 1 July 2026 – via Business Wire.